EUCTR2006-006390-24-DE进行中（未招募）不适用
Prospektive, randomized, controlled, multicentre, partly double blind study to compare Disci/Rhus toxicodendron comp., placebo and waiting list in patients with chronic low back pain.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •History of chronic low back pain (chronic local or pseudoradiculaere clow back pain due to e.g. degenerative basic illness).
- •=> Back pain for at least 12 month prior inclusion (= chronic low back pain).
- •Average value of pain intensity related to the last 7 days (40mm on a visual analog scale of 0 to 100mm).
- •Therapy of chronic low back pain only medicamentous in the last 4 weeks before enrollment (peripherally active analgesics, non-steroidal antiphlogistics, muscle relaxants).
- •=> effective contraception for women of childbearing potential. Methods of birth control are considered to effective, when failure rate is less than 1% per year, e.g. combined oral contraceptives, implants, IUDs, diphragm, occlusive pessary or sexual abstinence.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Treatment with Disci medicinal products.
- •Concomitant therapy with other drugs than peripheral active analgesic, non-steroidal antiphlogistics.
- •Necessity of taking analgesics due to other disease.
- •Protrusion or prolapse of one/more intervertebral disks with neurological symtomatic.
- •History of surgery of the spine or planned surgeries.
- •History of infectious spondylopathy.
- •History of back pain due to a malignant and inflammatory illness.
- •History of ankylosing spondylitis, Reiter´s syndrome, Morbus Behcet.
- •History of congenital malformation of spine expecting mild lordosis or scoliosis.
- •History of osteoporosis, spinal stenosis, spondylolysis, spondylolisthosis.
- •Physiotherapy within 4 weeks prior to inclusion or during study conduction.
- •Start of new therapy within 4 weeks prior to inclusion or planned new therapy.
- •Complementary medicine therapy (acupuncture, homeopathy, physiotherapy, neural therapy) within 4 weeks prior to inclusion or planned during study conduction.
- •Inability to complete the study according to protocol.
- •History of abuse of alcohol and drugs.
- •Participation in another study within 3 months prior to inclusion.
- •History of serious and/ or acute or chronic organic disease and mental disease.
- •=> History of coagulopathy and intake of drugs which inhibits coagulation.
- •Pregnant and breastfeeding females.
- •Current application for pension.
- •Involvement in the planning and conduct of the study.
- •Hypersensitivity of any ingredients of IMP.
研究者
相似试验
招募中
不适用
Prospective, randomized, controlled, multicenter, operative study to evaluate the role of intraoperative sonography compared to the preoperative wire localization in the treatment of non-palpable breast cancerC50Malignant neoplasm of breastDRKS00010174niversitätsfrauenklinik230
已完成
不适用
Prospective, multicenter, randomized, controlled, single-blind other clinical trial. What is the efficacy of pelvic floor biofeedback training with ACTICORE1® for stress incontinence?N39.3Stress incontinenceDRKS00027319ACTICORE GmbH124
尚未招募
Unknown
Prospective, multicenter, randomized, controlled, single-blind other clinical trial. What is the efficacy of app-based biofeedback training with ACTICORE1® for female stress incontinence?N39.3Stress incontinenceDRKS00033971ACTICORE GmbH262
进行中（未招募）
1 期
Multi-center, prospective, controlled, randomized, single-blinded study to evaluate the efficacy of vibrotactile neuro-feedback additionally to intake of Ginkgo biloba special extract EGb 761® for the treament of presby vertigo.Presby VertigoMedDRA version: 20.0 Level: PT Classification code 10047340 Term: Vertigo System Organ Class: 10013993 - Ear and labyrinth disordersEUCTR2014-000303-28-DEDr. Willmar Schwabe GmbH & Co. KG120
撤回
4 期
Prospective, Randomized, Controlled, Multicentre, Open Study Releas of Paclitaxel during PTA versus PTA alone for the treatment of de-novo occluded, stenotic or reoccluded, restenotic superficial femoral (SFA) or popliteal arteries.narrowing of the bloodvesselstenosis10003216NL-OMON35958Eurocor GmbH15